enzhou Kangning Hospital Co., Ltd.

mpany incorporated in the People's Republic of China

A C (**Supplementary Independent Investigation**) C A A 11, 2023, (**Supplementary Report of the Independent Investigation**) C A 12, 2023, C

Summary of Key Findings of the Supplementary Report of the Independent Investigation

Alleged Area I: Cash flows in the personal bank accounts of key financial personnel

A A C 1443:

1. A A 1443

2. (1443) C

3.

1. [illegible] B2,1[illegible]0,701 [illegible] B18,281,756.

2. [illegible]

3. [illegible]

Alleged Area III: Cash flows in the personal bank accounts of a senior management personnel

[illegible]

1. [illegible] 14 [illegible] 14 [illegible]

2. [illegible] 0 [illegible] 0.8 [illegible] .5 [illegible] 8([illegible])0.5 [illegible]

3. A C C

4. A C A C

A A

1. A

B A A 28, 2022 B15,816,447.
A C

(.) A C

(..) A C C A C

(...) A A A ,447. 447.

2.

3.

4.

Major Limitations on the Review Scope of the Supplementary Report of the Independent Investigation

[illegible]

(i) [illegible]

(ii) [illegible]

Opinions of the Independent Investigation Committee and the Board on the Supplementary Report of the Independent Investigation

[illegible]

[illegible] ([illegible] **Internal Control Adviser**) [illegible] C [illegible] A [illegible] 11, 2023, [illegible] C [illegible] (**Internal Control Review Report**) [illegible] A [illegible] 11, 2023 [illegible] C [illegible] A [illegible] C [illegible] A [illegible]

Purpose, Scope and Approach of Internal Control Review

[illegible] C [illegible] ([illegible]) [illegible] C [illegible] C [illegible]

[illegible] C [illegible] A [illegible] C [illegible]:

1. [illegible] C[illegible];
2. A [illegible]:
   (i) [illegible];
   (ii) [illegible];
   (iii) [illegible];
   (iv) [illegible];
   (v) [illegible];
   (vi) B [illegible];
   (vii) [illegible];
   (viii) [illegible];
3. [illegible]; [illegible]
4. [illegible].

Key Internal Control Issues	**Rectifications**
Entity-Level Review by COSO Framework	
Control Environment – Conflict of Interest Reporting Mechanism [illegible]	[illegible]

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Succession Plan [illegible]	[illegible]
Risk Assessments – Anti-Money Laundering Mechanism [illegible]	[illegible]

Key Internal Control Issues	Rectifications
Activity-level review	
Revenue and Accounts Receivable Management – Bad Debt Provision [illegible]	[illegible]
Bank and Cash Management – Charitable Donation Management [illegible]	[illegible]

Key Internal Control Issues	Rectifications
Activity-level review	
	[illegible] [illegible]

Views of the Internal Control Adviser

[illegible] 2022 [illegible] 2023. [illegible]

Views of the Audit Committee and the Board

[illegible]

[illegible]

CONTINUED SUSPENSION OF TRADING

[illegible] 9:00 [illegible] 1, 2022 [illegible]

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

[illegible]
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
[illegible]

[illegible]
[illegible] 14, 2023

[illegible]